Outlook Therapeutics Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| · | ||
|---|---|---|
| | | Page |
| | Cautionary Note Regarding Forward-Looking Statements and Industry Data | ii |
| | Selected Risks Affecting Our Business | iii |
| PART I | | 1 |
| ITEM 1. | Business | 1 |
| ITEM 1A. | Risk Factors | 27 |
| ITEM 1B. | Unresolved Staff Comments | 83 |
| ITEM 1C. | Cybersecurity | 83 |
| ITEM 2. | Properties | 84 |
| ITEM 3. | Legal Proceedings | 84 |
| ITEM 4. | Mine Safety Disclosures | 85 |
| | | |
| PART II | | 86 |
| ITEM 5. | Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities | 86 |
| ITEM 6. | Reserved. | 86 |
| ITEM 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 87 |
| ITEM 7A. | Quantitative and Qualitative Disclosures about Market Risk | 101 |
| ITEM 8. | Consolidated Financial Statements and Supplementary Data | 102 |
| ITEM 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 129 |
| ITEM 9A. | Controls and Procedures | 129 |
| ITEM 9B. | Other Information | 129 |
| | | |
| PART III | | 131 |
| ITEM 10. | Directors, Executive Officers and Corporate Governance | 131 |
| ITEM 11. | Executive Compensation | 131 |
| ITEM 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 132 |
| ITEM 13. | Certain Relationships and Related Transactions, and Director Independence | 132 |
| ITEM 14. | Principal Accounting Fees and Services | 132 |
| | | |
| PART IV | | 133 |
| ITEM 15. | Exhibits and Financial Statement Schedules | 133 |
In this report, unless otherwise stated or as the context otherwise requires, references to “Outlook Therapeutics,” “Outlook,” “the Company,” “we,” “us,” “our” and similar references refer to Outlook Therapeutics, Inc. (formerly known as Oncobiologics, Inc.) and its consolidated subsidiaries. The Outlook logo, Oncobiologics logo, LYTENAVA and other trademarks or service marks of Outlook Therapeutics, Inc. appearing in this report are the property of Outlook Therapeutics, Inc. This report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this report are the property of their respective holders.
Currency translations between Swiss Francs, or CHF, and U.S. dollars provided herein are based on the noon buying rate in New York City for cable transfers in foreign currencies as certified for customs purposes by the Federal Reserve Bank of New York on September 30, 2024, or CHF 0.9015 = $1.00. We do not represent that CHF were, could have been, or could be, converted into U.S. dollars at such rate or at any other rate.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.